Award
National Heart, Lung, and Blood Institute 11281051
2/2 Catheter Ablation Versus Antiarrhythmic and Heart Failure Drug Therapy in Preserved Ejection Fraction Heart Failure (CABANA-HF)
Recipient
Duke University
Award Amount
$1,571,639.00
Ceiling
$1,571,639.00
Awarded
July 09, 2026
Identifier
11281051
Award for a clinical trial evaluating catheter ablation versus drug therapy in heart failure patients with preserved ejection fraction, funded by NHLBI with $1.57 million for 2026-2033.
Description
This is a multi-center, randomized, open-label trial to evaluate catheter ablation for atrial fibrillation in patients with HFpEF. The primary endpoint is a composite of CV mortality or worsening HF. The project is funded by NHLBI with a total award amount of approximately $1.57 million for the fiscal year 2026. The project duration is from July 10, 2026, to June 30, 2033.